Pfizer/Eyetech's Macugen: Advisory Cmte. Wants Long-Term Follow Up
This article was originally published in The Pink Sheet Daily
Executive Summary
While the committee finds the existing data were sufficient for approval, members call for long-term follow up to address safety concerns and duration of therapy. The committee also recommends labeling address endophthalmitis.
You may also be interested in...
Pfizer/Eyetech Macugen To Launch In First Quarter With "Unambiguous" Label
The ophthalmic agent clears FDA under priority review procedures; "It is for all neovascular" age-related macular degeneration, Eyetech COO says. Company expects Macugen will receive broad coverage under Medicare Part B.
Pfizer/Eyetech Macugen To Launch In First Quarter With "Unambiguous" Label
The ophthalmic agent clears FDA under priority review procedures; "It is for all neovascular" age-related macular degeneration, Eyetech COO says. Company expects Macugen will receive broad coverage under Medicare Part B.
Pfizer Waiting On Macugen: “Stay Tuned,” CEO Says
Pfizer has not received any comments from FDA about issues with the pending ophthalmic agent Macugen, the company told analysts Nov. 30 in Groton, Conn